NEEDHAM, MA
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)THE ADENOID CYSTIC CARCINOMA RESEARCH FOUNDATION, founded in 2005, is a community nonprofit in the Medical Research sector that reported $1.9M in total revenue in fiscal year 2023. Revenue surged 37% from the prior year, signaling strong growth momentum.
THE ADENOID CYSTIC CARCINOMA RESEARCH FOUNDATION (ACCRF) SUPPORTS RESEARCH INTO ADENOID CYSTIC CARCINOMA THAT WILL ACCELERATE THE DEVELOPMENT OF IMPROVED THERAPIES AND A CURE FOR THE DISEASE.
TRANSLATION TO THE CLINIC: ACCRF SUPPORTS AND COORDINATES RESEARCH INTO TREATMENTS MOST LIKELY TO LEAD TO CLINICAL EBENFIT FOR ADENOID CYSTIC CARCINOMA PATIENTS. DRUG DISCOVERY, DRUG DEVELOPMENT...
TRANSLATION TO THE CLINIC: ACCRF SUPPORTS AND COORDINATES RESEARCH INTO TREATMENTS MOST LIKELY TO LEAD TO CLINICAL EBENFIT FOR ADENOID CYSTIC CARCINOMA PATIENTS. DRUG DISCOVERY, DRUG DEVELOPMENT, PRECLINICAL DRUG SCREENING AND CORRELATIVE STUDIES ARE CRUCIAL TO THE INITIATION AND OPTIMAL CONDUCT OF CLINICAL TRIALS.
BASIC RESEARCH: ACCRF SUPPORTS AND COORDINATES THE DESCRIPTIVE AND FUNCTIONAL STUDIES THAT IDENTIFY MOLECULAR TARGETS AND PATHWAYS THAT PERMIT ADENOID CYSTIC CARCINOMA TO PROGRESS. BY FOCUSING ON THE...
BASIC RESEARCH: ACCRF SUPPORTS AND COORDINATES THE DESCRIPTIVE AND FUNCTIONAL STUDIES THAT IDENTIFY MOLECULAR TARGETS AND PATHWAYS THAT PERMIT ADENOID CYSTIC CARCINOMA TO PROGRESS. BY FOCUSING ON THE MECHANISMS OF ACTION, RESEARCHERS MAY DISCOVER MORE QUICKLY THE ACHILLES' HEEL OF THE DISEASE.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2023 | 2022 | Change | |
|---|---|---|---|
| Revenue | $1,893,545 | $1,386,655 | +0.4% |
| Expenses | $1,872,720 | $1,618,196 | +0.2% |
| Net Income | $20,825 | $-231,541 | -1.1% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| JEFFREY A KAUFMAN | EXECUTIVE DIRECTOR/BOARD C | 50.00 |
Officer
Director
|
$150,000 | $0 | $150,000 |
| THOMAS DILENGE | BOARD VICE CHAIR | 5.00 |
Officer
Director
|
$0 | $0 | $0 |
| RALPH MOLLIS | TREASURER | 5.00 |
Officer
Director
|
$0 | $0 | $0 |
| MARNIE A KAUFMAN | DIRECTOR & CFO | 35.00 |
Director
|
$0 | $0 | $0 |
| ELIZABETH WEHLAGE | DIRECTOR | 5.00 |
Director
|
$0 | $0 | $0 |
| LISA BHAKRI | DIRECTOR | 5.00 |
Director
|
$0 | $0 | $0 |
| DAVID MORSE | DIRECTOR | 5.00 |
Director
|
$0 | $0 | $0 |
| BOZHO TODORICH | DIRECTOR | 5.00 |
Director
|
$0 | $0 | $0 |
| EMMA KINLOCH | DIRECTOR | 5.00 |
Director
|
$0 | $0 | $0 |
| NICOLE SPARDY BURR | DIRECTOR OF RESEARCH | 40.00 |
Highest
|
$135,000 | $0 | $135,000 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | No data | No data | No data | No data |
| 2023 | $1,893,545 | $1,872,720 | $2,690,770 | $20,825 |
| 2022 | $1,386,655 | $1,618,196 | $2,659,707 | $-231,541 |
| 2021 | $2,427,133 | $2,071,023 | $3,133,519 | $356,110 |
| 2020 | $1,208,448 | $1,420,993 | $2,608,038 | $-212,545 |
| 2019 | $2,103,655 | $1,225,852 | $2,646,923 | $877,803 |
| 2018 | $2,043,147 | $1,294,454 | $1,935,482 | $748,693 |
Compare THE ADENOID CYSTIC CARCINOMA RESEARCH FOUNDATION with other nonprofits in Massachusetts and across the country.